Home-based personalized exercise rehab for cardiorenal syndrome in HFrEF patients
Official title: Efficacy and Safety of Home-Based Exercise Rehabilitation in Patients With Cardiorenal Syndrome Complicated by Chronic Heart Failure With Reduced Ejection Fraction (HFrEF): A Randomized Controlled Trial
Run by Affiliated Hospital of Nantong University · NCT07167368 · Data updated 2026-11-12
This will test whether adding a personalized, home-based exercise program to standard heart-failure medications helps adults (18–75) with HFrEF and chronic kidney dysfunction (cardiorenal syndrome).
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Drugs / interventions | cart |
| Locations | 1 site (Nantong, Jiangsu) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07167368 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with chronically stable HFrEF (NYHA II–III), eGFR < 90 mL/min/1.73 m², and low exercise risk who can comply with home training and clinic visits.
✕Probably not a fit
Patients with uncontrolled hypertension, severe arrhythmias, significant valvular disease, severe pulmonary disease, major musculoskeletal limitations, or other listed exclusions are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, interventional trial will enroll 60 adults with chronic HFrEF and renal insufficiency and assign them 1:1 to standard drug therapy alone or standard therapy plus a tailored, home-based exercise rehabilitation program for 6 months. Exercise prescriptions are individualized using a two-step assessment protocol to set safe intensity and monitor tolerance, with periodic clinic visits for baseline and follow-up testing. Key functional outcomes include peak oxygen uptake (VO2 peak) and 6-minute walk distance, and safety monitoring will track arrhythmias, renal function, and other adverse events. The home-based model is chosen to improve long-term adherence and reduce barriers such as transportation while allowing personalized intensity adjustments for patients with dual organ dysfunction.
Why it matters
Potential benefit: If successful, adding home-based exercise could improve exercise capacity, functional status, and possibly cardiac and renal outcomes for patients with CRS and HFrEF.
How similar studies have gone: Exercise rehabilitation has improved cardiac function and exercise capacity in uncomplicated chronic heart failure, but its effects specifically in cardiorenal syndrome remain largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronically stable HFrEF complicated by kidney dysfunction (eGFR \< 90 mL/min/1.73m²) * NYHA class II-III * Low risk in exercise risk assessment * Aged 18-75 years Exclusion Criteria: * Uncontrolled hypertension * Severe arrhythmias (including frequent ventricular premature contractions, ventricular tachycardia, rapid atrial fibrillation, sick sinus syndrome, and second-degree or higher atrioventricular block) * Obstructive hypertrophic cardiomyopathy * Moderate to severe stenotic valvular heart disease * Deep vein thrombosis or pulmonary embolism * History of syncope * Severe anemia * Abnormal thyroid function * Severe pulmonary diseases * Mental illnesses * Osteoarticular or muscular diseases that impede rehabilitation training
Where it's running
-
The Affiliated Hospital of Nantong University
Nantong, Jiangsu, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using ultrasound to guide treatment for heart failure patients
This study is testing if using ultrasound to guide treatment can help hospitalized heart failure patients feel better by managing fluid buildup in their bodies.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Selective Cytopheretic Device (SCD) for heart and kidney failure patients awaiting LVAD
The Selective Cytopheretic Device (SCD) will be tried to reduce inflammation and help improve heart or kidney function in hospitalized patients with acute-on-chronic systolic heart failure and cardiorenal syndrome who are awaiting LVAD implantation.
-
Empagliflozin for kidney protection in cardiorenal syndrome type 1
This trial will test whether taking empagliflozin 10 mg compared with placebo helps protect the kidneys in adults hospitalized with acute heart failure who develop acute kidney injury.
-
Blood markers that may predict cardiorenal syndrome in people with chronic heart failure
This project will test whether five blood proteins (SLPI, Serpin E1, CXCL10, CXCL13, and Properdin) can predict cardiorenal syndrome in adults with stable chronic heart failure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.